Introduction: This study aimed to explore the value of a machine learning model based on spectral computed tomography (CT) for predicting the programmed death ligand-1 (PD-L1) expression in resectable non-small cell lung cancer (NSCLC). Methods: In this retrospective study, 131 instances of NSCLC who underwent preoperative spectral CT scanning were enrolled and divided into a training cohort (n = 92) and a test cohort (n = 39). Clinical-imaging features and quantitative parameters of spectral CT were analyzed. Variable selection was performed using univariate and multivariate logistic regression, as well as LASSO regression. We used eight machine learning algorithms to construct a PD-L1 expression predictive model. We utilized sensitivity, specificity, accuracy, calibration curve, the area under the curve (AUC), F1 score and decision curve analysis (DCA) to evaluate the predictive value of the model. Results: After variable selection, cavitation, ground-glass opacity, and CT40keV and CT70keV at venous phase were selected to develop eight machine learning models. In the test cohort, the extreme gradient boosting (XGBoost) model achieved the best diagnostic performance (AUC = 0.887, sensitivity = 0.696, specificity = 0.937, accuracy = 0.795 and F1 score = 0.800). The DCA indicated favorable clinical utility, and the calibration curve demonstrated the model’s high level of prediction accuracy. Discussion: Our study indicated that the machine learning model based on spectral CT could effectively evaluate the PD-L1 expression in resectable NSCLC. Conclusion: The XGBoost model, integrating spectral CT quantitative parameters and imaging features, demonstrated considerable potential in predicting PDL1 expression.
Lou et al. (Thu,) studied this question.